Tourmaline Bio, Inc. (TRML)
(Delayed Data from NSDQ)
$26.30 USD
+0.78 (3.06%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $26.28 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRML 26.30 +0.78(3.06%)
Will TRML be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRML
Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
Here's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price Strength
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'
Other News for TRML
Truist Financial Sticks to Its Buy Rating for Tourmaline Bio (TRML)
Piper Sandler Sticks to Its Buy Rating for Tourmaline Bio (TRML)
Tourmaline Bio management to meet with Truist
Keros Therapeutics appoints Chyung as CMO
Tourmaline Bio management to meet with Truist